Slow-releasing acipimox tablet

A technology of acipimox and sustained-release tablets, applied in the field of medicine, can solve the problems of diabetes and gout patients with exacerbation of disease, poor safety, and influence on glucose and uric acid metabolism pathways, etc. The effect of benefits and economic benefits

Inactive Publication Date: 2003-02-12
LUNAN PHARMA GROUP CORPORATION
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the safety of clinical use is relatively poor. In addition to nausea, abdominal pain, flushing, and skin itching, it can also affect the metabolic pathways of glucose and uric acid, aggravating the condition of patients with diabetes and gout.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Slow-releasing acipimox tablet
  • Slow-releasing acipimox tablet
  • Slow-releasing acipimox tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0025] Choose from eight specific prescriptions as follows:

[0026] Prescription A: Acipimox 375g

[0027] HPMC-4M 15g

[0028] 8% PVP absolute ethanol solution 150g

[0029] Magnesium Stearate 2g

[0030] Preparation process: Acipimox passes through a 100-mesh sieve, HPMC-4M passes through a 80-mesh sieve, weighs the prescribed amount of Acipimox and HPMC-4M, mixes them evenly, adds an appropriate amount of 8% PVP absolute ethanol solution, and granulates at 60°C Dried, 16-mesh sieve dry granules, add prescription amount of magnesium stearate to the dry granules, mix well, shape stamping tablets to get final product, about 850 tablets are obtained.

[0031] Prescription B: Acipimox 375g

[0032] HPMC-4M 80g

[0033] 8% PVP absolute ethanol solution 150g

[0034] Magnesium Stearate 2g

[0035] The preparation process is the same as prescription A.

[0036] Prescription C: Acipimox 375g

[0037] HPMC-15M 15g

[0038] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A slow-releasing acipimox tablet for regulating blood fat is prepared from acipimox, slow-releasing agent, adhesive and lubricant through proportioning, wet granulating, baking, mixing with lubricant, and tabletting. Its advantages are stable concentration of medicine in blood, durable acting and low toxic by-effect.

Description

Technical field [0001] The invention belongs to the medical technology, in particular to an acipimox sustained-release tablet, which is an efficient and safe blood lipid regulating drug. Background technique [0002] In recent years, with changes in eating habits, improvements in living standards, and increased work pressure, there are more and more patients with hyperlipidemia and hyperproteinemia, and the patient population is getting younger and younger. Hyperlipidemia and hyperproteinemia are a group of common clinical disorders of lipid metabolism. When the concentration of plasma lipid exceeds the upper limit of normal value, it is called hyperlipidemia (Hyperlipemia), and the lipoprotein in plasma exceeds the normal value. The high limit is called hyperlipoproteinemia (Hyperlipoproteinemia). Epidemiological studies have shown that increased levels of plasma low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) are important factors for premature ather...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/22A61K31/4965A61P3/06
Inventor 孙勇
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap